In addition to the genetic framework, there are two other critical requirements for the development of tissue-specific autoimmune disease. First, autoreactive T cells need to escape thymic negative selection. Second, they need to find suitable conditions for autoantigen presentation and activation in the target tissue. We show here that these two conditions are fulfilled in diabetic mice of the nonobese diabetic (NOD) strain. A set of autoreactive CD4 + T cells specific for an insulin peptide, with the noteworthy feature of not recognizing the insulin protein when processed by antigen-presenting cells (APCs), escaped thymic control, participated in diabetes and caused disease. Moreover, APCs in close contact with beta cells in the islets of Langerhans bore vesicles with the antigenic insulin peptides and activated peptide-specific T cells. Our findings may be relevant for other cases of endocrine autoimmunity.
Although autoimmune diabetic mice of the nonobese diabetic (NOD) strain have a wide range of autoreactivities 1 , the one directed against the insulin molecule is prominent 2 . T cells reactive to insulin have been identified in NOD mice and have been shown to transfer diabetes into nondiabetic mice [3] [4] [5] [6] [7] . T cells from T cell antigen receptor-transgenic mice specific for insulin are also diabetogenic 8 . Additional findings point to insulin as an important autoantigen for disease initiation. The amplitude of insulin expression in the thymus has been linked to diabetes incidence [9] [10] [11] [12] , and high expression of insulin in antigenpresenting cells (APCs) through the use of a transgene ablates diabetes development 13, 14 . Moreover, mice that express a mutant insulin gene product not recognized by T cells do not develop diabetes 7 . It is noteworthy that the T cell response to the insulin molecule is highly focused on a segment of the β-chain encompassing residues 9-23 (B:9-23) [15] [16] [17] [18] . This peptide binds poorly (with micromolar affinity and a high dissociation rate) to the major histocompatibility complex (MHC) class II molecule I-A g7 (refs. 18,19) . The finding that a small protein that yields a very weak binding peptide and circulates at nanomolar concentrations can function as an important autoantigen is unexpected and raises considerations about the molecular and cellular basis of autoreactivity. The present view is that weak binding MHC epitopes, such as those from the insulin B:9-23 peptide 18 or the insulin C-peptide 20 , may favor the development of autoreactivity because T cells specific for these epitopes and other weak binding epitopes may escape thymic selection 21, 22 .
Two sets of CD4 + T cells have been identified by studies of CD4 T cell responses to hen egg lysozyme (HEL) 23, 24 . One set, conventional T cells, called 'type A', respond to the protein and peptide presented by APCs. The second set, called 'type B', have the unique feature of responding only to peptides offered exogenously to the APC, not to the identical peptide derived from the processing of the protein. The peptides are identical but have different conformations when bound to the MHC class II molecules. It has been suggested that type B T cells directed to autologous proteins participate in autoreactivity induction [23] [24] [25] [26] [27] . Here we show that type B T cells specific for insulin appear spontaneously in diabetic NOD mice, along with weakly reactive type A T cells. The type B T cells react to intra-islet dendritic cells (DCs) containing the B:9-23 peptide and induce diabetes.
RESULTS

Insulin-reactive CD4 + type B T cells
We identified CD4 + T cells reactive to insulin in islets and the peripancreatic lymph nodes of prediabetic and early diabetic mice. We generated T cell hybridomas from these mice and found that 42 T cell hybridomas (7% of total) from 6 different fusions were reactive to insulin and/or to the B:9-23 peptide (617 hybridomas screened, of which 32 were further characterized). Many T cell hybridomas of the conventional type A responded to insulin as well as to B:9-23. Several T cell hybridomas were type B. They recognized only B:9-23, not the insulin molecule (Fig. 1a) . The distribution of type A and type B T cells was equal: among the 32 insulin-reactive CD4 + T cells characterized, 16 responded to peptide but not to insulin (type B) and an equal number, 16, responded to both (type A). The number was too small to derive definitive conclusions on their relative incidence. However, most of the type A T cells reacted weakly (in the low micromolar range) to either insulin or the peptide. About half of the type A T cells had an affinity to insulin that was 1-10% as much as their affinity to B:9-23, whereas the remaining T cells reacted equally to both (Fig. 1b,c) . We found both type A and type B T cell subsets in the peri-pancreatic node as well as within the infiltrated islets. These results indicated that type B T cells were specifically recruited to the islets together with weakly reactive type A T cells, which suggests the involvement of both type B and low-affinity type A T cells in the early disease process.
Mouse response to immunization with B:9-23
To examine in detail the immune response to insulin or to B:9-23, we immunized mice with one or the other and determined the incidence of type A and type B insulin-reactive CD4 + T cells. In NOD mice immunized with insulin, we detected few if any insulin-specific T cells in the draining lymph nodes ( Fig. 1d) . Published studies have detected a weak insulin T cell-proliferative response 14 . In contrast, we found a prominent CD4 + T cell response after immunization with B:9-23. The response was entirely blocked by antibody to I-A g7 (anti-I-A g7 ; Fig. 1e,f) . These T cells were peptide specific because they responded only to B:9-23, not to the insulin protein. Of 351 T cell hybridomas generated from the draining lymph nodes of the B:9-23-immunized mice, the majority (74%) were peptide specific, whereas only a small number (1.7%) recognized both peptide and the insulin molecule ( Fig. 1a-c and Supplementary Table 1 ). The remaining hybridomas were either unresponsive (17.7%) or autoreactive (6.6%). The type B T cells also recognized denatured insulin ( Supplementary Fig. 1a ), which indicated that they were not recognizing an artificial determinant arising from the synthetic peptide.
We next compared the insulin-reactive T cells from wild-type NOD mice and NOD mice with genetic deletion of both insulin genes that express a transgene encoding a mutant proinsulin 7 containing a single tyrosine-to-alanine amino acid substitution at residue 16 of the insulin β-chain (B16:A-dKO). In the absence of native insulin genes, the transgenic mutant insulin restores biological activity; however, the substitution abrogates recognition by insulin-specific T cells 7 . Unlike NOD mice, B16:A-dKO mice immunized with insulin generated a T cell response specific to insulin protein ( Fig. 1g ). Immunization of B16:A-dKO mice with B:9-23 generated a peptide response and a weak response to insulin ( Fig. 1h ). In addition, type A hybridomas generated from B16:A-dKO mice immunized with insulin showed a much greater sensitivity for insulin than that of hybridomas derived from wild-type NOD mice ( Fig. 1i) . This indicates that in the NOD mouse, high-affinity T cells to insulin are normally deleted. T cells found in peripheral tissue are less reactive, which reflects the fact that they escaped negative selection and bear the stamp of tolerance.
Different recognition of covalent peptide-MHC complexes
The explanation for the difference between the two sets of T cells in their recognition of the B:9-23-I-A g7 complex is unclear at present. Initial studies indicated that in contrast to the HEL system, H2-DM did not affect the development of type A or type B peptide-MHC (pMHC) complexes (data not shown). Moreover, H2-DM favored the assembly of B:9-23 with I-A g7 . We searched extensively for changes in the peptide or for post-translational modifications that may account for recognition by one or the other set of T cells and failed to identify any (data not shown). Both type A and type B CD4 + T cells reacted to purified I-A g7 molecules incubated with B:9-23 ( Supplementary Fig. 1b) . 
A r t i c l e s
The difference in recognition of B:9-23 by the two T cell types most probably reflects different conformational states of the pMHC complex.
In support of that interpretation, type A and type B T cells showed differences in their recognition of a covalently linked pMHC complex. The M12.C3 mouse B cell line engineered to express I-A g7 with the B:9-23 peptide covalently tethered 15 (M12.C3.G7β9-23) activated the type A T cells, including those that reacted weakly with insulin, but did not activate the type B T cells ( Fig. 1j and Supplementary Table 1) . Thus, the covalently linked complex was presented in a state or conformation that allowed recognition by the T cell antigen receptor of type A T cells but not by that of type B T cells. It is probable that the intracellular pathway by which insulin reaches the MHC class II molecule and the site in the APC are the two critical factors in generating a unique complex that T cells recognize.
Type B T cells cause diabetes
To determine if type B insulin T cells are diabetogenic, we generated 11 primary T cell lines from the draining lymph nodes of B:9-23immunized NOD mice, expanded them and adoptively transferred the cells into recipient mice of the NOD-severe combined immunodeficiency (NOD.SCID) strain. All of these T cell lines were type B, which meant they recognized B:9-23 but not the insulin molecule (Supplementary Fig. 2) . None of them recognized the covalently linked pMHC complex on M12.C3.G7β9-23 cells (data not shown). All T cell lines induced extensive insulitis, with 7 of 11 lines also inducing diabetes ( Fig. 2 and Supplementary Fig. 3a) .
Many of these lines also accelerated diabetes in young NOD mice ( Supplementary  Fig. 3) . The extent of disease transfer varied among the clones and was unrelated to cytokine profile ( Fig. 2b and Supplementary  Fig. 3a) . Thus, the peptide-reactive type B T cells could damage the islets and induce the same histopathology as other diabetogenic T cells, which suggests that they participate in the autoimmune process.
Presentation of B:9-23 by islet DCs
To address where insulin peptide presentation leading to the activation of type B T cells occurs, we examined APCs from various tissues. We did not detect antigen presentation to T cells by APCs from spleen, inguinal or peri-pancreatic lymph nodes from prediabetic mice (Fig. 3a) , which suggested that circulating insulin was not the source of peptide. In addition, neither DCs nor epithelial cells isolated from thymi activated type A hybridomas, which indicated that presentation in the thymus is quite low. Of all the tissue-specific APCs examined, the only APCs that presented insulin peptides to either type A or type B T cells were the intra-islet DCs (Fig. 3a) . In all mouse strains, the islets of Langerhans contain an average of about 10 DCs per islet, most of which constitutively express pMHC complexes derived from beta-cell proteins regardless of diabetic status, islet inflammation or beta-cell death 28 . Whole-islet cell fractions containing DCs or purified intraislet DCs from recombination-activating gene 1-deficient NOD mice (NOD Rag1 −/− mice) constitutively presented antigen to both type A and type B T cells in the absence of inflammation or overt cellular death (Fig. 3b,c) . Furthermore, when we incubated NIT-1 insulinoma cells, which do not express MHC class II molecules, with purified splenic DCs, we detected uptake of insulin granules by DC by electron microscopy (Fig. 3d) . These DCs were able to activate both type A and type B insulin-reactive T cells (Fig. 3e,f) , which showed that both pMHC conformers were presented by APCs in close contact with beta cells. The secretory granules of beta cells can constitute a source of the B:9-23 peptide because each granule is composed of about 1 × 10 6 insulin molecules, as well as catabolic products from its processing 29 . Incubation of purified secretory granules from primary beta cells with splenic DC led to robust activation of both type A and type B hybridomas (Fig. 3g) .
To assess whether these granules contained insulin peptides, we generated a monoclonal antibody that specifically binds to B:9-23 but not to insulin or proinsulin molecules (Supplementary Fig. 4) . We observed specific granule staining in whole islets and purified beta cells from NOD mice and NOD Rag1 −/− mice (Fig. 4) . The reaction was blocked by free peptide (Fig. 4b,e ) but not by an excess of insulin or proinsulin (Supplementary Fig. 4) . Cells containing B:9-23 + granules represented a subset of total beta cells. Most granules inside beta cells were positive for insulin but negative for B:9-23 and did not contain the lysosome marker LAMP-1 (CD107a; Fig. 4c and Supplementary Fig. 5) . In contrast, all vesicles containing B:9-23 in beta cells were positive for LAMP-1, and only very few of these vesicles (less than 10%) were also positive for insulin ( Supplementary Fig. 5 ). Confocal microscopy showed that most DCs in the islets had taken up B:9-23 + and/or insulin-positive granules (Fig. 4d,f) . Screening of purified islet DCs showed that about 80% of them contained insulin-positive granules, with an average of seven granules per DC. Many of these DCs stained positive for both insulincontaining vesicles and B:9-23-containing vesicles. Granules in islet DCs localized together with LAMP-1 and I-A g7 (Fig. 4g) , consistent with trafficking to cellular compartments involved in antigen processing and presentation. These observations suggest that B:9-23 peptides presented by I-A g7 could be derived from beta-cell vesicles containing peptides of the insulin β-chain and/or from the processing of insulin granules in DCs. Evidence of granules in intra-islet DCs under physiological conditions has been found by electron microscopy 26 . In addition, granules isolated from NIT-1 cells contained 8.8 nanomoles of material reactive to anti-insulin and 12 picomoles of material reactive to anti-B:9-23. Initial mass spectrometry of purified secretory granules showed that they contained not only C-peptide (data not shown) but also peptides from the B:9-23 segment, which included peptides centered on residues 12-21 (VEALYLVGGE) of the insulin β-chain (Supplementary Fig. 6) . These observations suggest that peptides immunogenic for type B T cells are produced during the physiological processing of mature insulin molecules and are not dependent on any prior inflammation.
DISCUSSION
We have distinguished three sets of insulin-reactive T cells in this study. One set had the unique feature of being specific to exogenous insulin peptide but unreactive to insulin. The peptide that activated these type B T cells was normally derived from the insulin secretory granule and was loaded on MHC class II in the intra-islet DC. These T cells were able to transfer diabetes and were present spontaneously in infiltrated islets, which indicates their participation in the autoimmune process. These T cells are compatible with the type B T cells described before [23] [24] [25] [26] .
The two other sets of T cells, called 'type A' here, were reactive to insulin and peptide but differed in their sensitivity to insulin. We identified one set in NOD mice and the other in B16:A-dKO mice. In the B16: A-dKO mice, we readily found type A T cells after insulin immunization, and they had a greater response to the insulin molecule and B:9-23 than did type A T cells from NOD mice. The strong insulin reactivity in B16: A-dKO mice supports the conclusion reached before that native insulin expression in the thymus influences the selection of insulin-reactive T cells and that partial tolerance or unresponsiveness to the insulin molecule exists in NOD mice [9] [10] [11] [12] . Thus, the few insulin-reactive T cells found in NOD mice had an 'imprint' of tolerance, with weak reactivity to insulin, which might explain why they escaped negative selection.
The frequency of type B T cells was much greater than that of type A T cells in the precursor population of NOD mice. However, because both type A and type B T cells were isolated from the islets, we cannot conclude which set is the main participant or if they act synergistically in disease development. More than one factor can influence the diabetogenicity of transferred T cells, such as time in culture and expression of adhesion molecules 30 . Because of this variability, we did not systematically make strict comparisons of the diabetogenicity of type A and type B T cells. Our results here and published reports 5, 8 indicate that both type A and type B insulin-specific T cells are diabetogenic. B:9-23 could be generated by DC handling of insulin after capture of insulin granules or from uptake of granules that already contained the peptide. The finding that islet DCs contained insulin and B:9-23 granules and the observation that 'feeding' DCs purified secretory granules resulted in strong presentation explains another conundrum about insulin presentation. There is a relatively poor yield of peptide selected by MHC molecules after protein processing 31 . Furthermore, because of the low binding affinity of B:9-23 for I-A g7 and the rapid dissociation of the peptide from I-A g7 (ref. 18 ), a high concentration of insulin in the APC is required for effective presentation to T cells. The concentration of insulin in blood and tissue is in the low nanomolar range. In antigen-presentation assays, the concentration of insulin or B:9-23 peptide required for presentation is in the low micromolar range, which is not physiological in the whole mouse. If all these aspects are taken into consideration, it is most likely that islet DCs are central to the presentation of insulin and insulin peptides, having two essential roles: to migrate into the pancreatic draining lymph nodes to initiate the sensitization process 32 , and to present antigen to sensitized T cells in the effector stage of diabetogenesis. Collectively these results suggest that self-reactive type B T cells and low-affinity type A T cells escape negative selection and give rise to pathogenic T cells in autoimmune diabetes. A situation akin to insulin autoimmunity may also be found in other endocrine autoimmune diseases such as autoimmune thyroiditis 33, 34 , in which a network of DCs surrounds endocrine cells that release secretory granules containing the hormones and products of catabolism.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
